Wedbush upgraded shares of Avalo Therapeutics (NASDAQ:AVTX - Free Report) to a strong-buy rating in a report issued on Thursday morning,Zacks.com reports.
A number of other brokerages have also recently commented on AVTX. HC Wainwright began coverage on shares of Avalo Therapeutics in a research report on Thursday, October 24th. They set a "neutral" rating on the stock. BTIG Research started coverage on shares of Avalo Therapeutics in a research report on Thursday, December 19th. They issued a "buy" rating and a $40.00 target price on the stock.
Check Out Our Latest Report on Avalo Therapeutics
Avalo Therapeutics Price Performance
Shares of Avalo Therapeutics stock traded down $0.55 during trading on Thursday, hitting $6.70. 24,581 shares of the stock traded hands, compared to its average volume of 62,744. The firm's fifty day moving average is $7.74 and its 200-day moving average is $9.32. Avalo Therapeutics has a 52 week low of $4.28 and a 52 week high of $34.46.
Institutional Trading of Avalo Therapeutics
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC grew its holdings in shares of Avalo Therapeutics by 998.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock worth $31,000 after purchasing an additional 3,754 shares during the last quarter. Marshall Wace LLP bought a new stake in Avalo Therapeutics in the 4th quarter worth $114,000. Walleye Capital LLC purchased a new position in shares of Avalo Therapeutics in the fourth quarter valued at about $145,000. Northern Trust Corp bought a new position in shares of Avalo Therapeutics during the fourth quarter valued at about $168,000. Finally, Bank of Montreal Can purchased a new stake in shares of Avalo Therapeutics during the fourth quarter worth about $446,000. Institutional investors own 87.06% of the company's stock.
About Avalo Therapeutics
(
Get Free Report)
Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.
Read More
Before you consider Avalo Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalo Therapeutics wasn't on the list.
While Avalo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
